Form 4: Samsara BioCapital Exchanges VTV Therapeutics Shares for Pre-Funded Warrants

Samsara BioCapital, a major shareholder of VTV Therapeutics, exchanged 58,836 shares of Class A Common Stock for pre-funded warrants exercisable for 58,885 shares at $0.01 per share.

Summary

• Samsara BioCapital, L.P. exchanged 58,836 shares of VTV Therapeutics Class A Common Stock for pre-funded warrants.
• The pre-funded warrants are exercisable for up to 58,885 shares of Class A Common Stock at an exercise price of $0.01 per share.
• The exchange was made on March 5, 2024, with no additional consideration paid by Samsara BioCapital.
• Samsara BioCapital GP, LLC, as the general partner of Samsara BioCapital, L.P., is deemed to beneficially own the securities.
• Dr. Srinivas Akkaraju, who has voting and investment power over the shares, may also be deemed to beneficially own the securities.
• The pre-funded warrants have no expiration date and are exercisable at any time after issuance.
• There is a limitation on exercising the warrants if it would result in the holder owning more than 9.99% of the outstanding Class A Common Stock.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction between a major shareholder and the company, indicating a continued investment interest. The sentiment is neutral to slightly positive as it shows continued engagement.

Positives

• The exchange provides Samsara BioCapital with the potential to increase its stake in VTV Therapeutics at a low exercise price.
• The pre-funded warrants have no expiration date, providing flexibility for future investment decisions.

Risks

• The exercise of the pre-funded warrants is limited if it would result in Samsara BioCapital owning more than 9.99% of the outstanding Class A Common Stock.
• The value of the warrants is dependent on the future performance of VTV Therapeutics' stock.

Future Outlook

The pre-funded warrants provide Samsara BioCapital with the option to increase its stake in VTV Therapeutics in the future, subject to certain ownership limitations.

Management Comments

• Srinivas Akkaraju, Managing Member of Samsara BioCapital GP, LLC, signed the SEC Form 4 on behalf of the company.

Industry Context

This transaction is a common method for investors to adjust their holdings in a company, often involving the exchange of shares for warrants or other securities.

Comparison to Industry Standards

• The exchange of common stock for pre-funded warrants is a relatively common practice in the biotech industry, particularly for investors seeking to maintain or increase their stake while managing their capital.
• Similar transactions can be seen with other biotech companies where large investors use warrants to manage their ownership and potential future upside.

Stakeholder Impact

• The transaction may have a minor impact on shareholders as it involves a change in the form of ownership for a major investor.
• The exchange does not directly impact employees, customers, or suppliers.

Next Steps

• Samsara BioCapital may exercise the pre-funded warrants in the future, subject to the ownership limitations.
• VTV Therapeutics will likely monitor the ownership changes and potential impact on its stock.

Key Dates

Keywords

Samsara BioCapital, VTV Therapeutics, pre-funded warrants, Class A Common Stock, share exchange, beneficial ownership, investment